- BLTE ยท Nasdaq
- Pharmaceutical Preparations
- San Diego, CA
- 41 employees
- CIK 0001889109
Updated from SEC filings through
Top things to know
Employees41As of December 31, 2025
Next earningsFebruary 11, 2027Estimated from past filings
Executives
- Yu-Hsin Lin Chief Executive Officer Form 4, September 9, 2026
- Hao-Yuan Chuang Chief Financial Officer Form 4, September 9, 2026
- Hendrik Peter Scholl Chief Medical Officer Form 4, June 22, 2026
- Nathan L. Mata Chief Scientific Officer Form 4, May 8, 2026
Belite Bio, Inc is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in San Diego, CA. It trades as BLTE on Nasdaq. It reported about 41 employees. Yu-Hsin Lin is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | Not on file | Not on file | Not on file | Not on file | Not on file |
| Operating income | -$84.2M 20-F, 2026-03-31 | -$40.0M 20-F, 2026-03-31 | -$31.7M 20-F, 2026-03-31 | -$12.8M 20-F, 2025-03-17 | -$9.8M 20-F, 2024-03-12 |
| SG&A | $38.8M 20-F, 2026-03-31 | $10.1M 20-F, 2026-03-31 | $6.8M 20-F, 2026-03-31 | $4.0M 20-F, 2025-03-17 | $2.4M 20-F, 2024-03-12 |
| Net income | -$77.6M 20-F, 2026-03-31 | -$36.1M 20-F, 2026-03-31 | -$31.6M 20-F, 2026-03-31 | -$12.6M 20-F, 2025-03-17 | -$9.7M 20-F, 2024-03-12 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Yu-Hsin Lin | Chief Executive Officer | Form 4, September 9, 2026 |
| Hao-Yuan Chuang CFO at Belite Bio | Chief Financial Officer | Form 4, September 9, 2026 |
| Hendrik Peter Scholl | Chief Medical Officer | Form 4, June 22, 2026 |
| Nathan L. Mata | Chief Scientific Officer | Form 4, May 8, 2026 |
Shares and governance
| Shares outstanding | 39.3 million (as of December 31, 2025) | 20-F, March 31, 2026 |
|---|---|---|
| Reportable segments | 1 (period ending December 31, 2025) | 20-F, March 31, 2026 |
| Auditor | Deloitte & Touche (Taipei, Taiwan) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 12, 2026 | Hendrik Peter Scholl Chief Medical Officer | Sale | 2,000 | $332K | Form 4, November 16, 2026 |
| October 1, 2026 | Hendrik Peter Scholl Chief Medical Officer | Sale | 500 | $83K | Form 4, October 5, 2026 |
| September 8, 2026 | Yu-Hsin Lin Chief Executive Officer | Sale | 100,435 | $19.1M | Form 4, September 9, 2026 |
| September 8, 2026 | Hao-Yuan Chuang Chief Financial Officer | Sale | 67,395 | $12.8M | Form 4, September 9, 2026 |
| August 12, 2026 | Hao-Yuan Chuang Chief Financial Officer | Sale | 367 | $66K | Form 4, August 14, 2026 |
| August 12, 2026 | Yu-Hsin Lin Chief Executive Officer | Sale | 365 | $66K | Form 4, August 14, 2026 |
| June 18, 2026 | Hendrik Peter Scholl Chief Medical Officer | Sale | 10,000 | $1.5M | Form 4, June 22, 2026 |
| June 16, 2026 | Hendrik Peter Scholl Chief Medical Officer | Sale | 10,000 | $1.4M | Form 4, June 17, 2026 |
Recent 8-K events
No 8-K filings on file.
Frequently asked questions about Belite Bio, Inc
- What does Belite Bio, Inc do?
- Belite Bio, Inc is classified by the SEC as Pharmaceutical Preparations (SIC 2834). It is based in San Diego, CA.
- How many employees does Belite Bio, Inc have?
- About 41 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Belite Bio, Inc?
- Yu-Hsin Lin, Chief Executive Officer, as named in a 4 filed September 9, 2026.
- Who is the CFO of Belite Bio, Inc?
- Hao-Yuan Chuang, Chief Financial Officer, as named in a 4 filed September 9, 2026.
- Where is Belite Bio, Inc headquartered?
- San Diego, CA.
- What is Belite Bio, Inc's stock ticker?
- BLTE on Nasdaq.
- What industry is Belite Bio, Inc in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Belite Bio, Inc's website?
- belitebio.com.
- When does Belite Bio, Inc report earnings next?
- February 11, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is Belite Bio, Inc a public company?
- Yes. Belite Bio, Inc files with the SEC under CIK 0001889109 and trades as BLTE.
- Who audits Belite Bio, Inc?
- Deloitte & Touche, Taipei, Taiwan, as named in its latest annual report (10-K).
- How many shares of Belite Bio, Inc are outstanding?
- 39.3 million shares as of December 31, 2025, from its 20-F filed March 31, 2026.
- How many business segments does Belite Bio, Inc report?
- 1 reportable segment for the period ending December 31, 2025, from its 20-F filed March 31, 2026.
- Have Belite Bio, Inc insiders traded stock recently?
- Since April 30, 2026, officers and directors reported 14 open-market sales worth about $36.2M and 0 purchases on Forms 4 and 5. The most recent: Hendrik Peter Scholl (Chief Medical Officer) sold 2,000 shares on November 12, 2026.